Nasal Vaccine (File Photo)
London: The Serum Institute of India (SII) has started a trial of the corona virus Nasal Vaccine in Britain. SII’s nasal vaccine is undergoing first phase trials. The Serum Institute of India will invest £ 24 million in the UK to expand its vaccine business and open a new sales office, which will create a large number of employment opportunities. Denmark bans Johnson & Johnson Corona vaccine
The UK Prime Minister’s Office announced this as part of a billion-pound Indo-UK trade promotion partnership, which will create around 6,500 new jobs in the UK. Around 20 Indian companies, along with Pune-based vaccine manufacturer, have announced significant investments in the UK in areas such as healthcare, biotech and software.
It has also been learned that the Serum Institute of India (SII) of India has also started a first stage trial in the UK for the corona virus nasal vaccine.
The UK Prime Minister’s Office said in reference to SII’s plans on Monday, “The sales office is expected to create more than one billion American new business, of which £ 200 million will be invested in the UK.” Gaya, ” Serum (SII) will be invested for clinical trials, research and development and manufacturing of vaccines. This will help Britain and the world defeat the corona virus epidemic and other deadly diseases. ”
In the healthcare sector, another Indian company, Global Gene Corp., will invest £ 59 million over the next five years.
Recently, 40-year-old SII CEO Adar Poonawalla told a London newspaper that he was constantly receiving threats from some chief ministers and corporate leaders. Because of which they have had to leave the country.